Cite
HARVARD Citation
Pettitt, A. et al. (n.d.). EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.. Hematological oncology. pp. 88-89. [Online].